Work

180eP Performance of HRD testing with QIAseq Targeted DNA Custom Panel HRD in ovarian cancer FFPE biopsies

Year: 2026

Type: article

Abstract: Homologous Recombination Deficiency (HRD) is a complex biomarker and directly impacts treatment decision-making in ovarian cancer (OC). Tumors harboring BRCA1 and/or BRCA2 mutations or HRD positive tumors are eligible for poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy. In Denmark, all patients diagnosed with high-grade OC (FIGO stage III or IV) or platinum-sensitive relapsed OC can be offered PARPi maintenance therapy. In this study we assessed the concordance between three methods for quantifying HRD status in OC patients.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.108226

Authors: M.G. Madsen, J.B. Noer, G. Andersen, H. Rasmussen, A.E. Soerensen

Institutions: Zealand University Hospital, Næstved Sygehus

Language: English

Topic: BRCA gene mutations in cancer

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910